Expression profile of metastasis-associated genes in esophageal squamous cell carcinoma

Abstract

The differentially expressed genes between esophageal squamous cell carcinoma (ESCC) with or without lymphatic metastasis were investigated by gene chip and the lymphatic metastasis-associated genes were screened out. Expression array was used to detect the mRNA from both the primary carcinoma and the corresponding esophageal epithelium in 15 cases of human ESCC. The lymphatic metastasis-associated genes were screened by bioinformatics between ESCC with or without lymphatic metastasis. The results showed that 43 (4.85%) genes significantly differed between the ESCC with and without lymphatic metastasis (P<0.05), of which 18 (2.03%) were upregulated and 25 (2.82%) down-regulated. The up-regulated genes were involved in cell adhesion molecules and cell membrane receptors and the down-regulated genes were mostly cell cycle regulators and intracellular signaling molecules. It was suggested that lymphatic metastasis-associated genes were screened by gene chip, which was helpful to understand the molecular mechanism of ESCC lymphatic metastasis and lymphatic metastasis-associated genes might be used as diagnostic markers and therapeutic targets for lymphatic metastasis.

Keywords

esophageal squamous cell carcinoma / gene chip / lymphatic metastasis / gene expression profile

References

[1] KwongK F. Molecular biology of esophageal cancer in the genomics era. Surg Clin North Am, 2005, 85(3): 539-553

[2] KurokawaS, ArimuraY, YamamotoH, et al. . Tumor matrilysin expression predicts metastatic potential of stage I (pT1) colon and rectal cancers. Gut, 2005, 54(12): 1751-1758

[3] BessonA, Gurian-WestM, ChenX, et al. . A pathway in quiescent cells that controls p27Kipl stability, subcellular localization, and tumor suppression. Genes Dev, 2006, 20(1): 47-64

[4] MuthusamyV, HobbsC, NogueiraC, et al. . Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer, 2006, 45(5): 447-454

[5] XuF, ZhongW, LiJ, et al. . Predictive value of EphA2 and EphrinA-1 expression in esophageal squamous cell carcinoma. Anticancer Res, 2005, 25(4): 2943-2950

[6] DasguptaS, Bhattacharya-ChatterjeeM, O'malleyB W, et al. . Tumor metastasis in an orthotopic murine model of head and neck cancer: Possible role of TGF-beta 1 secreted by the tumor cells. J Cell Biochem, 2006, 97(5): 1036-1051

[7] Xu L, Chen S, Bergan R C, MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene, 2006 Jan 16, [Epub ahead of print]

[8] TeraishiF, KagawaS, WatanabeT, et al. . ZD1839 (Gefitinib, ‘Iressa’), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anticancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett, 2005, 579(19): 4069-4075

[9] IwayaT, MaesawaC, KimuraT, et al. . Infrequent mutation of the human envoplakin gene is closely linked to the tylosis esophageal cancer locus in sporadic esophageai squamous cell carcinomas. Oncol Rep, 2005, 13(4): 703-707

[10] WanY. Gene expression-driven diagnostics and pharmacogenomics in cancer. Curr Opin Mol Ther, 2005, 7(3): 246-250

[11] CusterM C, RisingerJ I, HooverS, et al. . Characterization of an antibody that can detect the Kail/CD82 murine metastasis suppressor. Prostate, 2006, 66(6): 567-577

This project was supported by a grant of 2004 Henan Provincial Science and Technology Key Program Foundation (No. 0424410109).